Literature DB >> 14977414

The extracellular cyclic AMP-adenosine pathway in renal physiology.

Edwin K Jackson1, Dubey K Raghvendra.   

Abstract

Many cell types in the kidney express adenosine receptors, and adenosine has multiple effects on renal function. Although adenosine is produced within the kidney by several biochemical reactions, recent studies support a novel mechanism for renal adenosine production, the extracellular cAMP-adenosine pathway. This extracellular cAMP-adenosine pathway is initiated by efflux of cAMP from cells following activation of adenylyl cyclase. Extracellular cAMP is then converted to adenosine by the serial actions of ecto-phosphodiesterase and ecto-5'-nucleotidase. When extracellular cAMP is converted to adenosine near the biophase of cAMP production and efflux, this local extracellular cAMP-adenosine pathway permits tight coupling of the site of adenosine production to the site of adenosine receptors. cAMP in renal compartments may also be formed by tissues/organs remote from the kidney. For example, stimulation of hepatic adenylyl cyclase by the pancreatic hormone glucagon increases circulating cAMP, which is filtered at the glomerulus and concentrated in the tubular lumen as water is extracted from the ultrafiltrate. Conversion of hepatic-derived cAMP to adenosine in the kidney completes a pancreatohepatorenal cAMP-adenosine pathway that may serve as an endocrine link between the pancreas, liver, and kidney.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 14977414     DOI: 10.1146/annurev.physiol.66.032102.111604

Source DB:  PubMed          Journal:  Annu Rev Physiol        ISSN: 0066-4278            Impact factor:   19.318


  36 in total

Review 1.  The 2',3'-cAMP-adenosine pathway.

Authors:  Edwin K Jackson
Journal:  Am J Physiol Renal Physiol       Date:  2011-09-21

2.  Human monocytes respond to extracellular cAMP through A2A and A2B adenosine receptors.

Authors:  Ester Sciaraffia; Antonella Riccomi; Ragnar Lindstedt; Valentina Gesa; Elisa Cirelli; Mario Patrizio; Maria Teresa De Magistris; Silvia Vendetti
Journal:  J Leukoc Biol       Date:  2014-03-20       Impact factor: 4.962

3.  Probenecid Inhibits α-Adrenergic Receptor-Mediated Vasoconstriction in the Human Leg Vasculature.

Authors:  Michael Nyberg; Peter Piil; Oliver T Kiehn; Christian Maagaard; Tue S Jørgensen; Jon Egelund; Brant E Isakson; Morten S Nielsen; Lasse Gliemann; Ylva Hellsten
Journal:  Hypertension       Date:  2017-10-30       Impact factor: 10.190

Review 4.  CFTR chloride channel in the apical compartments: spatiotemporal coupling to its interacting partners.

Authors:  Chunying Li; Anjaparavanda P Naren
Journal:  Integr Biol (Camb)       Date:  2010-03-05       Impact factor: 2.192

Review 5.  Adenosine receptors and the kidney.

Authors:  Volker Vallon; Hartmut Osswald
Journal:  Handb Exp Pharmacol       Date:  2009

6.  Inactivation of multidrug resistance proteins disrupts both cellular extrusion and intracellular degradation of cAMP.

Authors:  Moses Xie; Thomas C Rich; Colleen Scheitrum; Marco Conti; Wito Richter
Journal:  Mol Pharmacol       Date:  2011-05-06       Impact factor: 4.436

7.  2',3'-cAMP, 3'-AMP, and 2'-AMP inhibit human aortic and coronary vascular smooth muscle cell proliferation via A2B receptors.

Authors:  Edwin K Jackson; Jin Ren; Delbert G Gillespie
Journal:  Am J Physiol Heart Circ Physiol       Date:  2011-05-27       Impact factor: 4.733

8.  The extracellular cAMP-adenosine pathway regulates expression of renal D1 dopamine receptors in diabetic rats.

Authors:  Eldo V Kuzhikandathil; Leslie Clark; Ying Li
Journal:  J Biol Chem       Date:  2011-07-29       Impact factor: 5.157

9.  Extracellular cAMP-adenosine pathways in the mouse kidney.

Authors:  Edwin K Jackson; Jin Ren; Dongmei Cheng; Zaichuan Mi
Journal:  Am J Physiol Renal Physiol       Date:  2011-06-08

10.  Skeletal muscle expresses the extracellular cyclic AMP-adenosine pathway.

Authors:  T Chiavegatti; V L Costa; M S Araújo; R O Godinho
Journal:  Br J Pharmacol       Date:  2007-12-24       Impact factor: 8.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.